Back

Changes in plasma lipid species following pravastatin treatment predict cardiovascular outcomes and represent a measure of the relative risk reduction in secondary prevention

26 August 2018 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 2 - Cardiovascular risk and its modification Lipid-Lowering Agents ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Peter John Meikle

Baker Heart and Diabetes Institute, Melbourne (Australia)

5 More presentations in this session

Presentation thumbnail
Miss M. Schreuder (Rotterdam, NL)
Abstract Slides
Presentation thumbnail
Professor S. Verma (Toronto, CA)
Abstract
Presentation thumbnail
Professor G. De Ferrari (Turin, IT)
Abstract Slides
Presentation thumbnail
Professor S. Bain (Swansea, GB)
Abstract Slides
Presentation thumbnail
Doctor D. Fitchett (Toronto, CA)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Cardiovascular risk and its modification

The Event

Event poster

ESC Congress 2018

26 August 2018 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Where are we now? Decision-making in LDL-C lowering and CV risk
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Webinar
New trial evidence in the field of lipid management

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources